



HAL
open science

Sensitivity and specificity of an acoustic- and perceptual-based tool for assessing motor speech disorders in French: the MonPaGe-screening protocol

Marina Laganaro, Cécile Fougeron, Michaela Pernon, Nathalie Lévêque, Stéphanie Borel, Maryll Fournet, Sabina Catalano Chiuve, Ursula Lopez, Roland Trouville, Lucie Ménard, et al.

► To cite this version:

Marina Laganaro, Cécile Fougeron, Michaela Pernon, Nathalie Lévêque, Stéphanie Borel, et al.. Sensitivity and specificity of an acoustic- and perceptual-based tool for assessing motor speech disorders in French: the MonPaGe-screening protocol. *Clinical Linguistics & Phonetics*, 2021, 35 (11), pp.1060-1075. 10.1080/02699206.2020.1865460 . hal-03099545

HAL Id: hal-03099545

<https://hal.science/hal-03099545v1>

Submitted on 4 Jan 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 *To appear in: Clinical Linguistics & Phonetics*

2

3 **Sensitivity and specificity of an acoustic- and perceptual-based tool for**
4 **assessing motor speech disorders in French: the MonPaGe-screening**
5 **protocol**

6 Marina Laganaro¹, Cécile Fougeron², Michaela Pernon^{2,3,8}, Nathalie Levêque^{2,4},
7 Stéphanie Borel⁵, Maryll Fournet^{1,3}, Sabina Catalano Chiuvé³, Ursula Lopez³,
8 Roland Trouville², Lucie Ménard⁶, Pierre R. Burkhard³, Frédéric Assal³,
9 Véronique Delvaux⁷

10

- 11 1. *Faculty of Psychology and Educational Sciences, University of Geneva, Switzerland*
12 2. *Laboratoire de Phonétique et Phonologie, UMR 7018, CNRS/Univ. Sorbonne Nouvelle, Paris,*
13 *France*
14 3. *Geneva University Hospitals and Faculty of Medicine, University of Geneva, Switzerland*
15 4. *APHP, Département de Neurologie, Hôpital Pitié-Salpêtrière, Centre Référent SLA, Paris,*
16 *France*
17 5. *APHP Sorbonne Université, GHU Pitié-Salpêtrière, Service d'ORL & Institut du Cerveau et*
18 *de la Moelle (ICM), Inserm/CNRS, Paris, France*
19 6. *Laboratoire de Phonétique, Université de Québec à Montréal, Canada*
20 7. *FNRS & IRSTL (Language Sciences and Technologies Research Institute), University of*
21 *Mons, Belgium*
22 8. *Centre de Référence Maladie Rare pour la maladie de Wilson, Service de Neurologie,*
23 *Fondation Rothschild, Paris.*

24

25 Running head : sensitivity & specificity of the MonPaGe-screening protocol

26 Keywords: motor speech disorders, screening, French, sensitivity, specificity

27 Word count:7632

28 **ABSTRACT**

29 To respond to the need of objective screening tools for motor speech disorders (MSD),
30 we present the screening version of a speech assessment protocol (*MonPaGe-2.0.0s*),
31 which is based on semi-automated acoustic and perceptual measures on several speech
32 dimensions in French. We validate the screening tool by testing its sensitivity and
33 specificity and comparing its outcome with external standard assessment tools. The data
34 from 80 patients diagnosed with different types of mild to moderate MSD and 62 healthy
35 test controls were assessed against the normative data obtained on 404 neurotypical
36 speakers, with *Deviance Scores* computed on seven speech dimensions (voice, speech
37 rate, articulation, prosody, pneumophonatory control, diadochokinetic rate, intelligibility)
38 based on acoustic and perceptual measures. A cut-off of the *MonPaGe total deviance*
39 *score (TotDevS) > 2* allowed MSD to be diagnosed with *specificity* of 95% and an overall
40 *sensitivity* of 83.8% on all patients pulled, reaching 91% when very mildly impaired
41 patients were excluded. A strong correlation was found between the MonPaGe TotDevS
42 and an external composite perceptual score of MSD provided by six experts. The
43 MonPaGe screening protocol has proven its sensitivity and specificity for diagnosing
44 presence and severity of MSD. Further implementations are needed to complement the
45 characterization of impaired dimensions in order to distinguish subtypes of MSD.

46

47 **Introduction**

48 Although both impaired language and impaired speech can be associated with a variety of
49 neurodegenerative pathologies and of acquired brain lesions, clinicians have at one's disposal
50 a large choice of language assessment and screening tools in many languages, while very
51 limited tools are available for the assessment of speech¹. In addition, the few assessment tools
52 available for motor speech disorders (MSD) in clinical practice are mostly based on perceptual
53 judgments. To complement the field of perceptual assessment tools for MSD, a consortium
54 made up of researchers and clinicians created the MonPaGe speech screening battery, which is
55 aimed at going beyond the perceptual-only judgments of speech and enabling more objective,
56 mainly acoustic-based, multiparametric quantification of speech disorders. Here, we test
57 whether the screening version of the protocol (MonPaGe-2.0.0s) can be reliably used as a
58 screening tool for the detection of MSD by assessing its specificity and sensitivity on a group
59 of 80 patients with various patterns of MSD and a group of neurotypical test controls against a
60 normative database gathered from 404 French-speaking healthy adults. Crucially, the potential
61 of the protocol to diagnose the presence of MSD in the patient group is tested by including
62 speakers with mild MSD in the patient cohort. The severity score obtained with the screening
63 protocol is also tested against an external assessment of the speech disorder severity provided
64 by a perceptually-based severity assessment made by six expert judges using a tool widely used
65 in French-speaking clinical settings.

66 *Motor speech disorders and their assessment*

67 Following acquired or degenerative brain disorders, speech can be impaired at different degrees
68 of severity and at different levels of the speech production process. Sub-types of MSD have

¹ Unless otherwise specified, voice is considered to be part of speech.

69 been determined at distinct levels. At a first branching, a distinction is made between dysarthria
70 and apraxia of speech (AoS). Dysarthria further groups several syndromes of impaired speech
71 which are the consequences of impaired control of the neuromuscular commands involved in
72 speech production, giving rise to altered voice and/or articulation and/or prosody and/or speech
73 rate (Duffy, 2005; McNeil, Robin, & Schmidt, 2008). Several subtypes of dysarthria are
74 traditionally distinguished (spastic, flaccid, hypokinetic, hyperkinetic, ataxic and mixed,
75 Darley, Aronson, & Brown, 1975; to which unilateral upper motor neuron dysarthria and
76 undetermined dysarthria have been added in more recent years, Duffy, 2005; 2013). AoS on the
77 other hand, refers to MSD that is not attributed to motor execution and control, but to impaired
78 phonetic planning (Blumstein, 1990; Code, 1998; Darley, Aronson & Brown, 1975; Varley &
79 Whiteside, 2001; Ziegler, 2008, 2009; Wertz, LaPointe & Rosenbek, 1984; McNeil et al.,
80 2008). AoS and dysarthria both result in altered articulation, speech rate and prosody, with an
81 overlap in the distortions observed in the dysarthric and AoS speech profiles.

82 Despite the fact that the two types of MSD share speech distortions and need to be
83 differentiated, most assessment tools have been developed separately for dysarthria and for AoS
84 (Dabul, 2000; Feiken, Hofstede, & Jonkers, 2008, Feiken & Jonkers, 2012; Strand, Duffy Clark,
85 & Josephs, 2014). For instance, the Apraxia Battery for Adults (ABA-2, Dabul, 2000) has been
86 conceived to assess AoS and is composed of tasks focusing on articulation, diadochokinetic
87 rate and non-verbal oral movements, but does not assess other parameters such as voice,
88 prosody or intelligibility; similarly, the AoS Rating Scale (ASRS, Strand et al., 2014) has been
89 conceived to specifically identify and describe the perceptual speech characteristics of AoS. On
90 the other hand, assessment tools have been developed specifically for dysarthria (among others,
91 for English: the Frenchay dysarthria assessment, Enderby & Palmer, 2008, which has been
92 adapted in several languages; for German: BoDys, Ziegler, Schölderle, Staiger, & Vogel, 2015;
93 for Dutch: The Radboud Dysarthria Assessment (RDA), Knuijt, Kalf, van Engelen, de Swart,

94 & Geurts, 2017; for French: The Batterie d'Evaluation Clinique de la Dysarthrie-BECD, Auzou
95 et al, 2006; 2019, the DIADOLAB, Menin-Sicard & Sicard 2020, see also the partial adaptation
96 of the Frenchay by Ghio, Giusti, Blanc, & Pinto,2019). These tools may be used to assess AoS
97 also, but they do not always include diadochokinetic rate or a comprehensive assessment of
98 articulation.

99 Whether conceived to assess dysarthria or AoS, speech assessment batteries available in clinical
100 practice mostly rely on perceptual classification of speech and voice disorders, often using a
101 large set of feature descriptors, which are well mastered only by SLP with an expertise in motor
102 speech disorders. There are some well-known downsides to the perceptual description of speech
103 features. First, the reliability and reproducibility of perceptual judgment of speech parameters
104 in MSD have often been questioned (Bunton, Kent, Duffy, Rosenbek, & Kent, 2007; Haley et
105 al., 2012). This is in particular the case when speech is assessed perceptually based on specific
106 dimensions, whereas better interrater agreement is observed on overall severity scores, at least
107 for trained raters (Ziegler, Staiger, Schröderle & Vogel, 2017). Although assessment is based
108 on a balance of subjective and objective evaluation in many domains, subjective evaluation is
109 preponderant in the perceptual assessment of specific speech parameters, as they rely on
110 individual internal representations that are based on the natural variability of these speech
111 parameters and that become somewhat shared with training, but not ascertained.

112 In the light of the acknowledged limitations of perceptual evaluation, acoustic analyses can be
113 of great help to quantify disordered dimensions in a clinical setting. Acoustic analyses have
114 been implemented in *voice* assessment clinical tools (e.g. AVQI: Maryn, De Bodt, & Roy, 2010;
115 Maryn, De Bodt, Barsties, & Roy, 2014; DSI: Wuyts et al., 2000), but have not systematically
116 been applied to other speech parameters such as speech rate, articulation or prosody, nor
117 generalised to assessment tools used in clinical practice. Hence, although global, holistic

118 perceptual impression represents the very first information available to the clinician in front of
119 the patients, tools are needed to further guide the assessment, combining functional, perceptual
120 judgments with objective acoustic descriptors of impaired speech parameters. One challenge of
121 this approach is to select a limited number of clinically-relevant descriptors, with no claim to
122 be exhaustive with regards to all potential measures. Indeed, there is a constantly growing
123 amount of measures, acoustic analyses and statistical techniques for characterizing a diversity
124 of aspects of the acoustics of dysarthric speech reported in the scientific literature. However,
125 they are typically very specific, quite sophisticated, not implemented as stand-up procedures in
126 the most popular softwares for voice and speech analysis, such as Praat (Boersma & Weenink,
127 2018) or the Multi-Dimensional Voice Program (MDVP, from Kay Elemetrics Corporation);
128 in short, they are not readily available for clinical purpose.

129 *The MonPaGe speech assessment protocol and the MonPaGe screening tool*

130 The MonPaGe speech assessment protocol (Fougeron et al. 2016, 2018; Pernon et al., 2020)
131 has been developed (1) to provide a comprehensive speech assessment tool for French-speaking
132 adults and (2) to integrate objective descriptors of potentially deviant speech parameters
133 obtained with acoustic analyses. The MonPaGe protocol integrates the main speech parameters
134 used to assess both AoS and dysarthria in clinical assessment tools. These parameters are
135 quantified either perceptually or acoustically, in a way that can be carried out by SLT or other
136 professionals qualified to assess speech but who do not necessarily have an expert competence
137 in acoustic phonetics or speech engineering. The MonPaGe-2.0.0s presented here is a screening
138 version based on a subset of speech dimensions and parameters from the MonPaGe protocol
139 and aimed at detecting speech patterns that deviate from normal conditions. A speech screening
140 tool should allow to determine whether the patient's speech deviates from typical speech, how
141 much it deviates, and on which speech parameters. This usually corresponds to the first step in

142 clinical assessment. The second step, namely an in-depth speech assessment contributing to the
143 differential diagnosis of subtypes of MSD, goes beyond the aims of the screening tool.

144 In order to consider MonPaGe-2.0.0s as a valid screening tool for MSD, the tool should be
145 sensitive enough to detect most patients with a clinical diagnosis of MSD, even with mildly
146 disordered speech (high sensitivity), and at the same time it should be specific enough to avoid
147 over diagnosis, i.e. to avert diagnosing healthy speech as disordered (high specificity). In
148 addition, the assessment given with MonPaGe-2.0.0s should present similar trends to the ones
149 observed with other assessment methods which are already widely used in clinical practice,
150 such as perceptual-only evaluations.

151

152 **Method**

153 *Population*

154 *Reference group: healthy speakers*

155 For the reference values on the speech dimensions tested in MonPaGe, a group including 404
156 neurotypical speakers aged 20-93 years was selected from the MonPaGe_HA (for Healthy
157 Adults) database of spoken French (Fougeron et al., 2018). Participants were recruited in 4
158 French-speaking locations: Mons, Belgium ($n = 104$); Montréal, Canada ($n = 103$); Paris, France
159 ($n = 101$); Geneva, Switzerland ($n = 97$). All participants spoke French as their primary language
160 (mother tongue) and currently used language. The population recruited for the MonPaGe_HA
161 database is balanced within and between countries on sex (209 women and 195 men) and age
162 groups ([20-39], [40-49], [50-59], [60-74], [75+]) (see Fougeron et al., 2018 for more details).

163 In order to provide normative data based on the largest possible relevant groups of speakers,
164 the entire database was split into three age groups: younger speakers aged 20 to 59 years old

165 [20-59] (N = 231, 119 women, mean age = 41.81, SD = 11.44), and older speakers further split
166 into two groups [60-74] (N = 94, 48 women, mean age = 66.01, SD = 4.31) and [75-93] (N =
167 79, 42 women, mean age = 81.71, SD = 4.30). This choice was driven by a first screening of
168 the data which confirmed findings in the literature showing little evidence of age effects on
169 speech between 20 and 60. The two oldest speakers groups include less speakers but were kept
170 as subgroups in response to clinical needs, where appropriate reference values based on such
171 partition are needed for the elderly.

172 Participants were recruited in the local communities through public advertisements and among
173 relatives. Distribution of educational level (age of finishing school) was wide and similar across
174 countries, with a median age of finishing school at 22 years old (range: 13 to 48). Speakers in
175 the oldest group (>75) were also screened for language and cognitive deficits (with either the
176 e-GeBAS, Chicherio et al., 2019, or MMSE, Folstein, Folstein, & McHugh, 1975).

177

178 *Test group 1: Speakers with MSD*

179 80 patients aged 24 to 81 (mean age = 57.1) diagnosed with mild to moderate MSD recruited
180 in France (Pitié-Salpêtrière University Hospital and Lariboisière Hospital, Paris), in French-
181 speaking Switzerland (Geneva University Hospitals) and French-speaking Belgium (Hôpital
182 André Vésale, Charleroi University Hospital) were included for the validation. In order to vary
183 the speech profiles, patients with MSD associated with six different underlying pathologies
184 were included, namely Parkinson disease (PD), Amyotrophic Lateral Sclerosis (ALS),
185 Friedreich ataxia (FA), Kennedy disease (spinal and bulbar muscular atrophy, SBMA), Wilson
186 disease (WD), and post-stroke AoS. The neurological diagnosis was established by neurologists
187 in the hospitals where patients were recruited. To be included in the present study, the patients
188 had to be French native speakers, present mild or moderate acquired or progressive speech

189 difficulty noticed by the patient and a SLP, no or only very mild language impairment. Patients
190 with diagnosed dementia or psychiatric disorders and patients with history of developmental
191 speech and language disorders or hearing impairment were excluded. Table 1 presents the
192 distribution and description of the patients over the six clinical groups with associated basic
193 descriptors.

194 The speech of each of the 80 patients was assessed by six experts (either SLP or clinical
195 phoneticians) on a perceptual basis. A Composite Perceptual (hereby “CP”) score, equivalent
196 to the BECD’s perceptual score (Auzou & Rolland-Monnoury, 2006) was computed based on
197 a perceptual rating of the participant’s speech on five dimensions: voice quality, segmental
198 realization, prosody, intelligibility and naturalness of speech. Each dimension was assessed on
199 a 5-point scale (0: normal to 4: severely impaired) on the recording of a sample of about 2 min.
200 of continuous read speech. The composite perceptual score ranging from 0 to 20 was obtained
201 by summing the five scores.

202

203 *(Table 1 about here)*

204 *Test group 2: healthy control speakers*

205 62 neurotypical French-speaking control participants who were not included in the reference
206 group were recruited in Geneva. They were aged 22 to 88 (mean age = 53.4, 21 men) and had
207 no history of neurological disease or speech and language disorders.

208

209 The study was approved by the local ethic committees at the institutions where the participants
210 were recruited. All participants signed informed consent before participating in the study.

211

212 *Speech material and speech descriptors*

213 The MonPaGe protocol assesses different speech dimensions based on a variety of tasks (a
214 detailed description of the MonPaGe protocol is provided in Fougeron et al., 2018). Here, a
215 subset of the original speech descriptors was retained for the MonPaGe-2.0.0s screening tool
216 for MSD, providing information on seven dimensions, namely: intelligibility, articulation,
217 pneumophonatory control, voice, prosody, speech rate and diadochokinetic rate. These
218 dimensions have been selected in agreement with the expert SLT associated with the project,
219 based on (i) dimensions that are most used in clinical practice and in other assessment tests and
220 (ii) a balance between the time necessary to assess each dimension and its informativity. Note
221 that the speech descriptors resulting from this procedure, although each relating to a specific
222 dimension, have not the ambition to reflect all the potential disorders on that dimension of
223 speech. Ultimately, they have been selected for their typicality, because they represent the
224 participant's level of competence on that dimension, and/or for their informativity (with respect
225 to the aim of developing a screening tool for MSD), not for the sake of comprehensiveness. For
226 example, prosody is assessed in the extensive MonPaGe protocol via several acoustic and
227 perceptual measures of the distinctive, demarcating and expressive functions of intonation in
228 French, as exhibited by the reading of a tale and the production of selected sentences. In the
229 end, only the ability to express an interrogation via melodic modulations is incorporated in the
230 screening tool. Similarly, pneumophonatory control is indexed by, but by no means reducible
231 to, the indicator of maximum phonation time, which is very commonly used in clinical practice,
232 although its relationship with laryngeal and respiratory physiology is admittedly highly
233 complex (e.g. Solomon et al., 2000).

234 The seven speech dimensions, the associated speech tasks and the resulting selective descriptors
235 are detailed below. The measurements were carried out off-line using a computerized tool
236 integrating perceptual tasks for scoring intelligibility, coding pseudo-words errors, etc. and a

237 customized Praat script dedicated to human supervision of acoustic measurements.

238 *Intelligibility.* A short intelligibility test was administered in the form of an interactive task
239 between the experimenter and the participant in a face-to-face setting. The participant was asked
240 to instruct the experimenter to place some test-words on a 5x5 grid combining icons of various
241 shapes and colors, using a pre-learned carrier sentence (“Place the word [target_word] on the
242 [color] [shape]” (e.g. ‘Place the word “dog” on the red circle’). The color-shapes combinations
243 were of limited number, while target words were drawn from a database of 437 picturable
244 French words: each target word had one to six competitors (phonological minimal pairs, along
245 five types of phonological contrast, namely place of articulation, voice, manner of articulation,
246 nasality/cluster and vowel quality) within the database and possibly more in the French lexicon.
247 For each session/speaker, a randomization procedure randomly extracted 15 times a target and
248 a specific color-shape combination (corresponding to a particular location on the grid). The
249 participant, but not the experimenter, saw each target picture and corresponding written word
250 on the appropriate grid location on the computer screen and gave instructions to the
251 experimenter, who had to write each target word on a paper grid.

252 The final *intelligibility score* of the participant was computed based on examination of the paper
253 grid, as the number of test words not understood correctly by the experimenter during the
254 interaction (independently of the location on the grid). A rating of 1 was given to incorrect
255 responses, and 0.5 when two responses (including the correct response, e.g. “desert”/”dessert”
256 for “dessert”) were provided.

257 *Articulation.* Articulatory precision was assessed on the production of a set of 50 pseudo-words,
258 covering the articulation of most of the French consonants and vowels as well as consonant
259 clusters.

260 Pseudoword production was elicited via the bimodal presentation of each target (in an
261 orthographic form on a screen and in an audio form via headphones), to minimise errors due to
262 pseudo-word reading difficulties or to misperception. Regarding the assessment of articulation
263 accuracy, errors on targeted consonants, vowel and syllables were listed based on perceptual
264 assessment following a guided coding procedure for each pseudo-word, where questions were
265 targeted on specific phoneme and on potential types of errors (distortion, substitution, omission,
266 insertion). The computerized tool allowed the raters to play each pseudoword as needed and
267 score targeted phonemes or syllables as correct or incorrect. Overall, 151 targeted phonemes or
268 syllables included in the 50 pseudowords were scored per speaker and a descriptor related to
269 articulation accuracy is expressed in terms of a *number of errors* (from 0 to a maximum of 151).
270 The pseudo-word production is used as a screening for articulatory precision in MonPaGe-2.0
271 as only the total number of errors is considered and can be easily extracted via the guided
272 computerized scoring tool, but it has been conceived to be used also for further more detailed
273 assessments.

274 *Maximum phonation time (MPT)*. As a standard measure of pneumo-phonatory control, a
275 descriptor representing maximum phonation time over a sustained vowel was computed.
276 Participants were instructed to produce a sustained vowel /a/ as long as possible after taking a
277 maximal inhalation, at a comfortable pitch and at their habitual loudness. The task was repeated
278 as many times as needed and two productions were recorded. The duration of the two trials of
279 the sustained /a/ production was measured with Praat and the best performance selected as the
280 *maximum phonation time (MPT)*.

281 *Voice*. Voice-related measures were based on a sustained production for 2-3 seconds of the
282 vowel /a/ at a comfortable height and loudness and on the reading of a 7 syllables sentence
283 composed of only voiced sounds (“Mélanie vend du lilas” - [melanivãdylila], ‘Melanie sells

284 *lilac*'). All measurements were computed with Praat, using a semi-automatic procedure: a
285 customized Praat script was developed to guide the non expert user so that s/he can adjust the
286 relevant settings for optimal results at each stage of the procedure.

287 A first set of standard descriptors of voice quality was taken on the first 2 seconds of the
288 sustained /a/ vowel. These included the two short-term (cycle-to-cycle) measures of vocal
289 instability in terms of frequency and amplitude: jitter and shimmer, respectively. These were
290 computed with Praat as the five-point Period Perturbation Quotient (*a_Jitter-PPQ5*) and the
291 11-point Amplitude Perturbation Quotient (*a_Shimmer-APQ11*). Instability in vocal fold
292 vibration over the whole 2-second window was assessed in terms of f0 standard deviation
293 (*a_SDF0*), potentially allowing for the detection of vocal tremor. Presence of a noise component
294 during the vowel was measured in terms of a harmonic-to-noise ratio (*a_HNR*) and possible
295 dysphonia was also assessed with the smoothed cepstral peak prominence measure (*a_CPPs*)
296 (Hillenbrand et al., 1994).

297 A second set of descriptors related to the speaking voice was measured on the longer continuous
298 read speech sample "Mélanie vend du lilas". On the f0 time series computed over the whole
299 sentence, mean (*speaking_meanf0*) and standard deviation (*speaking_SDF0*) were computed.
300 The smoothed cepstral peak prominence was also taken from the whole voiced sentence
301 (*speaking_CPPs*).

302 *Prosodic contrast.* The production of an assertive vs. interrogative prosodic contrast was tested
303 on a four syllables fully voiced sentence 'Laurie l'a lu' ([loʁilaly], 'Laurie read it'). The
304 sentence was first presented on the screen as a declarative and read by the speaker. Then the
305 speaker was asked to say the same sentence again but asking a question, while the sentence was
306 presented with a question mark.

307 The prosodic contrast between the two modalities was computed in terms of a difference in f0
308 modulation over the sentence. In the interrogative condition marked by a large final rise of f0
309 in French, expected a large delta in f0 range between the first half and the second half of the
310 sentence is expected. This ambitus was expected to be smaller in the assertive condition,
311 although it was not inexistent if the speaker produces a large f0 fall at the end of the assertion,
312 or an initial rise at the beginning of it. Therefore, the prosodic contrast was expressed as the
313 difference between the two modalities in these f0-range deltas between the beginning and the
314 end of the sentence. The recorded sentences were automatically split into two parts, and f0
315 range was computed in semitones for the first and second parts. The descriptor for prosodic
316 contrast achievement was thus computed as:

317 $(f0_{\text{range@end}} - f0_{\text{range@begin}})_{\text{question}} - (f0_{\text{range@end}} - f0_{\text{range@begin}})_{\text{assertion}}$

318 *Speech rate.* Speech rate was assessed on a short sentence reading task. The duration of the
319 sentence “Mélanie vend du lilas” ([melanivãdylila], ‘Melanie sells lilac’) was measured with
320 Praat and a simple measure of speech rate was obtained by dividing the expected number of
321 phonemes (14 phonemes) by this duration.

322 *Diadochokinetic (DDK) rate.* Maximum repetition rates with oral *diadochokinetic* tasks are
323 often used in clinical practice to test the ability to make alternating articulatory movements in
324 quick and accurate succession. Seven items, which vary in terms of phonological complexity,
325 were used here. They included standard sequences used to compute alternative motion rate
326 (AMR) with the repetition of a CV syllable (AMR_{CV}) or a CCV syllable (AMR_{CCV}). Different
327 CV and CCV syllables were used to target alternating movements with different articulators:
328 jaw/lips with /ba/, front part of the tongue with /de/, tongue body with /go/, constrictions with
329 /kla/, and front to back with /tɾa/. Finally, a repetitive sequence /badego/ was used to compute
330 a sequential motion rate (SMR_{CV}). Participants were instructed to produce these sequences in a

331 continuous manner for at least five second as fast and as accurately as possible.

332 The number of phonemes produced over an interval of about 4 seconds of continuous repetition
333 was used as an index of DDK rate for AMR_{CV} , AMR_{CCV} , SMR_{CV} . This interval was selected
334 from the onset of the speech waveform and was manually adjusted to the right in order not to
335 cut the last syllable if needed. Also, in order to capture difficulties in the repetition of the same
336 syllables (AMR) vs. the repetition of a sequence of three syllable (SMR) which could be found
337 for speakers with AoS for instance (e.g. Ziegler, 2002), we also computed the difference
338 between the sequential motion rate and the alternative motion rate averaged over all CV
339 sequences: ($SMR_{CV} - AMR_{CV}$).

340 *Procedure and analyses*

341 All the participants underwent the MonPaGe protocol following the standard assessment
342 procedure with speech and speech-language pathologists in clinical settings for the patients and
343 in a standard room at the University for the controls. The MonPaGe protocol was run on a
344 laptop and speech samples were recorded using either a head-mounted or a table microphone
345 depending on the place of recruitment. This variability in recording reflects the variations across
346 clinical settings and has also been introduced in the recordings of the reference group (see
347 Fougeron et al., 2018). The assessment takes about 20 minutes with typical speakers and 30
348 minutes with patients with moderate MSD (Pernon et al., 2020), and the same duration is
349 necessary for scoring.

350 *Constitution of the norms from the reference healthy speakers group*

351 The productions of the 404 healthy speakers reference group were analyzed in order to obtain
352 normative values. For each descriptor, missing data and extreme values (below and above the
353 1st/99th percentiles) were first removed. In order to account for sex or age-group effects on the

354 norms, linear models were first computed in R with Sex (male/female) and Age-group ([20-
355 59], [60-74], [75+]) as between-subject factors and the various descriptors as dependent
356 variables. Whenever an effect of Sex or an interaction with Age-group was found, further
357 analyses were carried out for the male and female speakers separately. Inter-group differences
358 for the Age-group predictor were tested with Tukey post-hoc tests. Results from these statistical
359 analyzes are provided in the supplementary material. Normative values for each descriptor was
360 then computed by subgroups accordingly. Since groups split or merging were done according
361 to the sex or age effects, the number of participants retained for the computation of normative
362 values varied according to the descriptor considered.

363 *Computation of deviance scores*

364 For each descriptor, the speech of the participants in the two test groups (patients and healthy
365 controls) were compared to the normative values of the reference population, according to its
366 sex and age group.

367 A *deviance score* (*DevS*) spanning from 0 to 4 was defined for each descriptor depending on
368 its distance from the reference value. The standard limit from the normative data was fixed at
369 centile 5 (Brooks, Sherman, Iverson, Slick, & Strauss, 2011) and five degrees of *DevS* are defined,
370 with *DevS* = 0 standing for no-deviant (within normal range) and *DevS* = 4 for excessively
371 deviant, according to the position of the speaker's descriptor value relative to the reference
372 distribution. Cut-off values for defining these deviance degrees are determined according to
373 either the tails of the distribution (c5/c95 and c1/c99, for the *DevS* = 1 and *DevS* =2
374 respectively) and further severity, beyond c1/c99, is computed based on the inter-centile
375 distance between c50 and c5/c95, as detailed in Table 2.

376

377 (Table 2 about here)

378

379 For the dimensions of voice quality and DDK performance, which rely on several descriptors,
380 a composite deviance score was further computed as detailed in Table 3. Finally, each
381 participant's speech is globally characterized by the *MonPaGe total score* (*TotalDevS*, ranging
382 from 0 to 32); which corresponds to the sum of the deviant scores on the seven speech
383 dimensions, where larger scores indicate more deviance in speech.

384 (Table 3 about here)

385 The detailed procedures for the assessment of sensitivity, specificity and external validity are
386 described along with the results.

387 **Results**

388 ***Reference values***

389 The normative values for each descriptor obtained from the 404 healthy speakers reference
390 group are presented in Appendix A (Tables A.I and A.II). Normative values for each descriptor
391 and for each age/sex subgroup are presented in terms of mean, median and standard deviation,
392 except for intelligibility and segmental errors for which median and maximum error rates are
393 provided. Distribution tails of the population's scores are also given with the 1st/99th, 5th/95th
394 and 10th/90th percentiles, in order to provide possible cut-off scores of the normal performance
395 limits. According to the descriptor, the tails of interest for the determination of the cut-off scores
396 are either on the upper or lower sides (e.g. for error values, alteration is to be found in the upper
397 tail while 0 error is normal).

398

399 ***Specificity and sensitivity of MonPaGe***

400 Appendix B and C present the deviant scores per speech dimension and *TotalDevS* for each of
401 the 80 patients and 62 healthy test controls, respectively. The *MonPaGe TotalDevS* ranges from
402 0 to 12 in the patient group and from 0 to 4 in the healthy test control group.

403 The cut-off score for a diagnosis of MSD with MonPaGe was defined by plotting sensitivity
404 versus specificity for the few possible cut-off scores (from 1 to the maximum MonPaGe
405 *TotalDevS* in the test control group). The best cut-off score was a **MonPaGe *TotalDevS* > 2**
406 with a *specificity* of 95.2% and *sensitivity* of 83.8%. Figure 1 illustrates how sensitivity varies
407 according to patients' severity as assessed externally with the Composite Perceptual Score. It
408 can be observed that sensitivity raises to 92% when excluding patients with very mild
409 impairments (CP score $\leq 4 / 20$).

410 (*Figure 1 about here*)

411 For the *external validity*, the composite perceptual score of severity was considered the clinical
412 gold standard. Pearson correlation computed between the MonPaGe *TotalDevS* and the external
413 CP score on the 80 patients is $r(80) = .737$, $p < .0001$.

414 **Discussion**

415 The sensitivity and specificity in the diagnosis of MSD of the MonPaGe screening protocol
416 based on a set of semi-automated acoustic measures and on targeted perceptual measures was
417 assessed on the speech from 80 French-speaking patients diagnosed with a diversity of mild to
418 moderate MSD and 62 healthy test controls against the normative data of 404 neurotypical adult
419 speakers. On each of the seven speech dimensions (voice, speech rate, articulation, prosody,
420 pneumophonatory control, diadochokinetic rate, intelligibility) a deviance score (*DevS*) was
421 calculated for each participant with reference to the normative data and an overall deviance

422 score, the MonPaGe *TotalDevS*, was computed as the sum of all *DevS*. With a cut-off score at
423 MonPaGe *TotalDevS* > 2, the *specificity* of the tool was excellent (95%), and its sensitivity
424 was very high, in particular for the mild to moderate patients (sensitivity > 92% when the
425 patients with very mild MSD are excluded). Along with the strong correlation between the
426 MonPaGe *TotalDevS* and an external composite perceptual assessment of severity obtained
427 from 6 expert judges, the present results indicate that the MonPaGe protocol is a reliable
428 screening tool for assessing the presence of MSD and its severity.

429 The current study has two crucial features related to the specificities of the analyses in the
430 MonPaGe protocol and to the population involved in the study, which will be discussed in
431 further detail below.

432 ***Guided objective analyses of impaired speech***

433 As exposed in the introduction, the available clinical assessment tools for MSD are mostly
434 based on perceptual judgment, which are bound to rely heavily on subjective evaluation. For
435 these reasons the MonPaGe assessment protocol relies mainly on descriptors extracted from the
436 acoustic signal for five out of the seven dimensions (voice, MPT, speech rate, prosodic contrast
437 and DDK rate). For the other two dimensions (intelligibility and articulation accuracy), the
438 descriptors are not objective in the sense of ‘acoustic’, but are not purely subjective either. In
439 the functional intelligibility testing, the clinician writes down his/her understanding of the word
440 pronounced by the patient and the matching with the intended word produced by the patient is
441 done *off-line* during the scoring procedure, a procedure which has been used previously to
442 assess intelligibility (Kent, 1992; Miller, 2013; Yorkston & Beukelman, 1978; Weismer, 2008).
443 Here the intervention of a human listener is needed since the very notion of intelligibility refers
444 to how adequately the intended targets are actually perceived by an interlocutor. In the
445 assessment of articulation accuracy, the scoring of segmental errors on pseudo-words is

446 essentially relying on perceptual judgments. It should be noticed however that this assessment
447 is also done off-line: the clinician follows a guided coding procedure for each pseudo-word,
448 where questions are targeted on specific phonemes and on potential types of distortions. To
449 answer these questions, the clinician/scorer can listen to each production as many times as
450 necessary. Inter-rater agreement was evaluated for pseudo-word scoring, as this measure
451 involves some amount of subjective assessment. Two different raters (an expert and a recently
452 qualified SLP) independently scored the 151 target phoneme/syllables in the pseudo-word
453 module for 20 patients (5 with PD, 5 ALS, 5 WD and 5 AoS). The mean inter-rater agreement
454 on the 3020 observations was very high (98.94%, Cohens' Kappa = 0.89). With this off-line
455 scoring procedure we thus obtained a very high inter-rater agreement between two clinicians
456 on a significant subpart of the validation data.

457 Overall, the MonPaGe protocol takes advantage of objective descriptors of impaired speech
458 parameters obtained via semi-automatic acoustic analyses or via targeted/guided coding of the
459 intended production. Acoustic analysis has the advantage of releasing the clinicians from
460 subjective descriptions, but it has the drawback of being time-consuming and relying on specific
461 expertise. An assessment tool combining perceptual and easy-to-obtain acoustic information
462 seems to represent a good balance taking advantage of the two approaches while minimizing
463 their respective drawbacks. For MonPaGe-2.0.0s, a semi-automatic acoustic analyses routine
464 was developed to be easily performed with minimal intervention and minimal acoustic-phonetic
465 knowledge. These interventions typically required to check the automatic segmentation of the
466 onsets-offsets of analysis windows in the audio files, and to adjust some key parameters in the
467 case of noisy recordings. Then, the automatic extraction of acoustic measures on the various
468 speech parameters, followed by their automated comparison with normative data defined on a
469 large reference population (404 speakers) free the clinicians from the many pitfalls of a
470 heuristic, subjective approach to clinical evaluation. To date, the MonPaGe-2.0.0s screening is

471 based on a relatively limited set of well-defined acoustic descriptors and is quite performant.

472 Objective measures should also facilitate a fast and effective communication among clinicians
473 and should ensure a good/quality screening of MSD even when done by clinicians without
474 expert competence in acoustics and phonetics.

475 *Validation on a variety of MSD*

476 The few available MSD assessment tools often lack a validation procedure, or they have been
477 validated on very specific subtypes of MSD (e.g. progressive AoS vs. progressive aphasia in
478 Strand et al., 2014; dysarthria associated with Parkinson disease in Cardoso et al., 2017) or on
479 cohorts of patients with a large variety of dysarthria subtypes but without a grouping approach
480 (Knuijd et al., 2017; DeBiagi et al., 2018). In the current study, the MonPaGe screening tool
481 has been validated on a group of 80 patients encompassing a large diversity of types of MSD,
482 including AoS following stroke, dysarthria associated to PD, to ALS, to FA, to WD and to
483 Kennedy disease. Thus, as a screening tool, the MonPaGe protocol presents overall good
484 performance in the diagnosis of the presence and severity of impaired speech for a variety of
485 patterns of MSD. There are however some speech parameters which need to be improved in
486 future implementations of MonPaGe. First, 25 patients with MSD displayed impaired
487 intelligibility scores, but some patients with severe impairment of articulation displayed
488 intelligibility scores within the normal range. This observation may related to the difficulty to
489 measure intelligibility and call for further improvement, although the relationship between
490 intelligibility and articulatory errors is not necessarily linear as articulatory errors may be
491 predicted by the listener and therefore comprehensible (Coppens-Hofman et al., 2016). Second,
492 prosodic contrasts and maximum phonation time scores were deviant in very few patients. This
493 may be due to low sensitivity of these specific tasks or to the fact that these parameters were
494 within normal range in our group of patients with mild to moderate MSD and should be

495 specifically clarified in future. Finally, a further step will also be to achieve differential
496 diagnosis for different subtypes of MSD by enriching the screening tool with specific speech
497 descriptors and possibly additional speech tasks/materials.

498

499

500 **Acknowledgment**

501 This research was partly supported by Swiss National Science Foundation grants no. CRSII5_173711,
502 by the Belgian FNRS grant 33663575 (CDR UltraAeroSpeech) and the program "Investissements
503 d'Avenir" ANR-10-LABX-0083 (Labex EFL). The work was also possible thanks to funding from the
504 French Friedreich Ataxia Association, and from Parkinson Suisse. The normative data could not have
505 been constituted without the help of (a) other collaborators of the MonPaGe project: Pellet P., Bagou
506 O., Kocjancic-Antolik T. and (b) our students: Blanchard C., Baradat Garcia A., Cohen T., Davat H., de
507 Braquillanges A, de Laubier C., Dehon S., Leclerc-Poudrier A., Mabut C., Maysounave M., Miny A.,
508 Pochat-Baron M., Rary E., Vidou C., Van Malderen S., Visentini A.

509

510

511

512 **Declaration of interest statement**

513 The authors report no conflict of interest

514 **References**

- 515 Auzou, P., & Rolland-Monnoury, V. (2019). *BECD : Batterie d'Evaluation Clinique de la*
516 *Dysarthrie*. Ortho-Edition, Isbergues, France.
- 517 Boersma, P & David Weenink, D. (2018). Praat: doing phonetics by computer [Computer
518 program]. Version 6.0.37, retrieved from <http://www.praat.org/>
- 519 Blumstein, S. (1990). Phonological deficits in aphasia: Theoretical perspectives. In A.
520 Caramazza (Ed.), *Cognitive neuropsychology and neurolinguistics* (pp. 33-53).
521 Hillsdale: Lawrence Erlbaum.
- 522 Brooks, L. B., Sherman, E. M. S., Iverson, G. L., Slick, D. J., & Strauss E. (2011). Psychometric
523 Foundations for the Interpretation of Neuropsychological Test Results. In Schoenberg,
524 M. R. & Scott, J. G. (Eds). *The little Black Book of Neuropsychology*. Springer, New
525 York
- 526 Bunton, K., Kent, R. D., Duffy, J. R., Rosenbek, J. C , & Kent, J. F. (2007). Listener agreement
527 for auditory-perceptual ratings of dysarthria. *Journal of Speech, Language, and Hearing*
528 *Research, 50*, 1481–1495.
- 529 Cardoso, R., Guimarães, I., Santos, H., Loureiro, R., Domingos, J., de Abreu, D., Gonçalves,
530 N., Pinto, S., & Ferreira, J. (2017). Frenchay dysarthria assessment (FDA-2) in
531 Parkinson's disease: cross-cultural adaptation and psychometric properties of the
532 European Portuguese version. *Journal of Neurology, 264(1)*, 21–31.
533 doi:10.1007/s00415-016-8298-6
- 534 Chicherio, C., Genoud-Prachex, T., Assal, F., & Laganaro, M. (2019). *E-GeBAS: Electronic*
535 *Geneva Bedside Aphasia Scale*. [Computer program]. retrieved from
536 <https://www.unige.ch/fapse/logotools/fr/adultes>
- 537 Code, C. (1998). Major review: Models, theories and heuristics in apraxia of speech. *Clinical*
538 *Linguistics and Phonetics, 12*, 47–65.
- 539 Coppens-Hofman, M. C., Terband, H., Snik, A. F., & Maassen, B. A. (2016). Speech
540 Characteristics and Intelligibility in Adults with Mild and Moderate Intellectual
541 Disabilities. *Folia phoniatica et logopaedica, 68(4)*, 175–182.
542 <https://doi.org/10.1159/000450548>
- 543 Dabul, B. (2000). *Apraxia battery for adults (2nd ed)*. Austin, TX: Pro-Ed.
- 544 Darley, F. L., Aronson, A. E., & Brown, J. R. (1975). *Motor Speech Disorders*. Philadelphia,
545 PA: W.B. Saunders.

546 De Biagi, F., Frigo, A.C., Andrea, T., Sara, N., Berta, G., & Meneghello, F. (2018). Italian
547 validation of a test to assess dysarthria in neurologic patients: a cross-sectional pilot
548 study. *Otolaryngology*, 8, 343. DOI: 10.4172/2161-119X.1000343

549 Duffy, J. (2005). *Motor speech disorders*. St Louis, MO: Mosby Elsevier

550 Duffy, J. R. (2013). *Motor speech disorders: Substrates, differential diagnosis, and*
551 *management* (3rd ed.). St. Louis, MO: Elsevier Mosby.

552 Enderby, P., & Palmer, R. (2008). *FDA-2: Frenchay Dysarthria Assessment* (second edition).
553 Austin, PRO-ED.

554 Feiken, J., & Jonkers, R. (2012). *Diagnostisch instrument voor apraxie van de spraak [DIAS;*
555 *Diagnostic Instrument for Apraxia of Speech]*. Houten, The Netherlands: Bohn, Stafleu
556 en Van Loghum.

557 Fougeron, C., Delvaux, V., Ménard, L., & Laganaro, M. (2018). The MonPaGe_HA database
558 for the documentation of spoken French throughout adulthood. *Proceedings of the*
559 *Eleventh International Conference on Language Resources and Evaluation* (LREC
560 2018), L18-1679.

561 Fougeron C., Delvaux V., Pernon M., Lévêque N., Borel S., Pellet P. Bagou O., Trouville R.
562 Ménard L., Catalano S., Lopez U., Kocjancic-Antolik T., Laganaro M. (2016).
563 MonPaGe: un protocole informatisé d'évaluation de la parole pathologique en langue
564 française. In Joyeux N. & Topouzkhianian S., (eds) *Actes du colloque UNADREO*
565 *Orthophonie et technologies innovantes* . Chapitre 14.

566 Feiken, J., Hofstede, G., & Jonkers, R. (2008). De diagnostiek van verbale apraxia [The
567 diagnosis of verbal apraxia]. *Logopedie en Foniatrie*, 7/8, 228-234.

568 Folstein, M.F., Folstein, S.E., & McHugh, P.R. (1975). "Mini-mental state". A practical method
569 for grading the cognitive state of patients for the clinician. *Journal of Psychiatric*
570 *Research*, 12(3), 189-198. doi:10.1016/0022-3956(75)90026-6

571 Ghio, A., Giusti, L., Blanc, E., & Pinto, S. (2019). French adaptation of the "Frenchay
572 Dysarthria Assessment 2" speech intelligibility test. *European annals of*
573 *otorhinolaryngology, head and neck diseases*. DOI: 10.1016/j.anorl.2019.10.007

574 Haley, K. L., Jacks, A., de Riesthal, M., Abou-Khalil, R., & Roth, H. L. (2012). Toward a
575 quantitative basis for assessment and diagnosis of apraxia of speech. *Journal of Speech,*
576 *Language, and Hearing Research*, 55(Suppl.), S1502–S1517.

577 Hillenbrand, J., Cleveland, R.A., & Erickson, R.L. (1994). Acoustic correlates of breathy vocal
578 quality. *Journal of Speech Language and Hearing Research*, (37), 769-778.

579 Jonkers, R., Feiken, J., & Stuive, I. (2017). Diagnosing apraxia of speech on the basis of eight
580 distinctive signs. *Canadian Journal of Speech-Language Pathology and Audiology*, *41*,
581 303-319.

582 Kent, R. D. (Ed.). (1992). *Intelligibility in speech disorders: Theory, measurement and*
583 *management* (Vol. 1). John Benjamins Publishing.

584 Knuijt, S., Kalf, J.G., van Engelen, B.G.M., de Swart, B.J.M. & Geurts, A.C.H. (2017) The
585 Radboud Dysarthria Assessment: development and clinimetric evaluation. *Folia*
586 *Phoniatica et Logopaedica*. *69(4)*, 143-153. doi: 10.1159/000484556

587 Lansford, K.L., Liss, J.M., & Norton, R.E. (2014). Free-classification of perceptually similar
588 speakers with dysarthria. *Journal of Speech, Language, and Hearing Research*. *57(6)*,
589 2051-64.

590 Liss, J.M., LeGendre, S, & Lotto, AJ. (2010). Discriminating dysarthria type from envelope
591 modulation spectra. *Journal of Speech, Language, and Hearing Research*, *53(5)*, 1246-
592 55

593 Maryn, Y., De Bodt, M., Barsties, B., & Roy, N. (2014). The value of the Acoustic Voice
594 Quality Index as a measure of dysphonia severity in subjects speaking different
595 languages. *European Archives of Oto-Rhino-Laryngology*, *271*, 1609-1619.

596 Maryn, Y., De Bodt, M., & Roy, N. (2010). The Acoustic Voice Quality Index: toward
597 improved treatment outcomes assessment in voice disorders. *Journal of Communication*
598 *Disorders*, *43*, 161-174.

599 McNeil, M. R., Robin, D. A., & Schmidt, R. A. (2008). Apraxia of speech: Definition and
600 differential diagnosis. In M. R. McNeil (Ed.), *Clinical Management of Sensorimotor*
601 *Speech Disorders* (2nd ed., pp. 249–268). New York, NY: Thieme.

602 Menin-Sicard, A. & Sicard, E. (2020). Outils de mesures et d'évaluation objective de la
603 phonologie, de la fluence et de la prosodie avec DIADOLAB3. *Rééducation*
604 *orthophonique*, *281*, pp.131-168.

605 Miller, N. (2013). Measuring up to speech intelligibility. *International Journal of Language &*
606 *Communication Disorders*, *48(6)*, 601-612.

607 Pernon, M., Levêque, N., Delvaux, V., Assal, F., Borel, S., Fougeron, C., Trouville, R.,
608 Laganaro, M. (2020). MonPaGe, un outil de screening francophone informatisé
609 d'évaluation perceptive et acoustique des troubles moteurs de la parole (dysarthries,
610 apraxie de la parole). *Rééducation Orthophonique*, *281*, 171-197.

611

- 612 Strand, E. A., Duffy, J. R., Clark, H. M., & Josephs, K. (2014). The Apraxia of Speech Rating
613 Scale: a tool for diagnosis and description of apraxia of speech. *Journal of*
614 *Communication Disorders*, 51, 43–50. doi:10.1016/j.jcomdis.2014.06.008
- 615 Varley, R. & Whiteside, S. (2001). What is the underlying impairment in acquired apraxia of
616 speech. *Aphasiology*, 15, 39–49.
- 617 Weismer, G. (2008). Speech intelligibility. In Ball MJ, Perkins M, Müller N, Howard S
618 (eds): *The Handbook of Clinical Linguistics*, pp 568–582. Oxford, Blackwell
- 619 Wertz, R., LaPointe, L., & Rosenbek, J. (1984). *Apraxia of speech in adults. The disorder and*
620 *its management*. New York, NY: Grune and Stratton.
- 621 Wuyts, L.R., De Bodt, M.S., Molenberghs, G., Remacle, M., Heylen, L., Millet, B., Van Lierde,
622 K., Raes, J., & Van de Heyning, P.H. (2000). The dysphonia severity index: an objective
623 measure of vocal quality based on a multiparameter approach. *Journal of Speech,*
624 *Language, and Hearing Research*, 43(3):796-809.
- 625 Yorkston, K. M., & Beukelman, D. R. (1978). A comparison of techniques for measuring
626 intelligibility of dysarthric speech. *Journal of Communication Disorders*, 11(6), 499-
627 512.
- 628 Ziegler, W. (2002). Task-related factors in oral motor control: Speech and oral diadochokinesis
629 in dysarthria and apraxia of speech. *Brain and Language*, 80(3), 556–575.
- 630 Ziegler, W. (2008). Apraxia of speech. In: Goldenberg, G. and Miller, B. L., (eds)
631 *Neuropsychology and Behavioral Neurology*, ed. 3, p. 269-286. Edinburgh: Elsevier.
- 632 Ziegler, W. (2009). Modelling the architecture of phonetic plans: Evidence from apraxia of
633 speech. *Language and Cognitive Processes*, 24(5), 631-661.
- 634 Ziegler, W., Aichert, I., & Staiger, A. (2012). Apraxia of speech: Concepts and controversies.
635 *Journal of Speech, Language, and Hearing Research*, 55, S1485-S1501.
- 636 Ziegler, W., Schölderle, T., Staiger, A. & Vogel, M. (2015). The Bogenhausen Dysarthria
637 Scales (BoDyS): A Standardized Test for the Clinical Assessment of Dysarthria in
638 Adults. *Sprache Stimme Gehör*, 39 (04), 171-175. DOI: 10.1055/s-0041-102792
- 639 Ziegler, W., Staiger, A., Schölderle, T., Vogel, M. (2017). Gauging the auditory dimensions of
640 dysarthric impairment: reliability and construct validity of the Bogenhausen Dysarthria
641 Scales (BoDyS). *Journal of Speech, Language, and Hearing Research*, 60, 1516–1534
- 642

643 - .

644

645 Tables

646 **Table 1.** Patient distribution over the 6 clinical groups and associated descriptors: sex, age,
647 origin and severity measured with the Composite Perceptual (CP) score.

648 **Table 2.** Calculation of deviance scores (*DevS*) used in the MonPaGe screening protocol
649 (c=centiles, SD=standard deviations from the reference distribution)

650 **Table 3.** Descriptors and deviant scores for each of the 7 speech dimensions

651


652

653

654 **Figure caption**

655 **Figure 1.** sensitivity of the MonPaGe screening protocol, with a MonPaGe *TotalDevS* cut-off
656 score at >2, according to severity level of the population assessed with the external composite
657 perceptual score, ranging 0 to 20 (where 1 to 6 is considered mildly impaired, 7 to 13 moderate,
658 14 to 16 severe and > 16 very severe).

659



660

661 **Appendices**

662 **Appendix A.**

663 **Table A.I.** Normative values for the descriptors for the 7 dimensions in terms of mean, standard
664 deviation (sd) and median, and distribution tails (1st, 5th, 10th, 90th, 95th and 99th percentiles).
665 Tails that are informative for the determination of the DevS are presented in bold.

666

667 **Table A.II.** Reference values for Intelligibility (in terms of number of word not recognized over
668 15 words) and articulation accuracy (in terms of segmental errors over 151 targets). Centiles 1,
669 5, 50, 95, 99 and maximum error.

670

671 **Appendix B.**

672 Deviant scores (DevS) per dimensions and MonPaGe total deviance score (TotalDevS) for each
673 of the 80 patients.

674

675 **Appendix C.**

676 Deviant scores (DevS) per dimension and MonPaGe total deviance score (TotalDevS) for each
677 of the 35 test controls.

678

679 **Appendix A.**

680 **Table A.I.** Normative values for the descriptors for the 7 dimensions in terms of mean,
 681 standard deviation (sd) and median, and distribution tails (1st, 5th, 10th, 90th, 95th and 99th
 682 percentiles). Tails that are informative for the determination of the *DevS* are presented in
 683 bold.

		Sex	Age Group	n	mean	sd	media n	1st	5th	10th	90th	95th	99th
VOICE	a_Jitter-PPQ5 (%)	f	20-93	173	0.25	0.13	0.22	0.09	0.11	0.13	0.41	0.47	0.65
		m	20-59	107	0.27	0.14	0.25	0.1	0.12	0.16	0.41	0.47	0.89
			60-74	44	0.3	0.15	0.26	0.1	0.12	0.13	0.55	0.63	0.69
			75-93	30	0.37	0.2	0.32	0.15	0.16	0.17	0.59	0.79	0.89
	a_Shimmer-APQ11 (%)	f	20-59	102	3	1.98	2.51	0.9	1.02	1.17	5.89	7.1	8.59
			60-93	67	4.56	3	4.09	1.06	1.22	1.37	8.51	9.48	12.57
		m	20-59	108	4.63	2.56	3.84	0.93	1.58	1.89	8.5	9.03	11.12
			60-93	75	5.85	2.84	5.52	1.29	1.91	2.35	9.71	11.28	11.81
	a_SDf0 (Hz)	f	20-59	103	3.77	2.05	3.31	1.14	1.41	1.8	6.5	7.4	10.58
			60-74	38	4.63	2.14	4.19	1.37	2	2.43	7.67	9.33	9.83
			75-93	29	4.96	2.91	3.75	2.02	2.36	2.57	10.69	11.52	11.71
		m	20-74	152	2.92	1.8	2.41	0.95	1.18	1.26	4.99	6.61	8.95
			75-93	29	5.09	2.64	4.53	1.58	1.98	2.45	8.32	9.07	10.98
	a_CPPs (dB)	f	20-93	171	15.55	2.32	15.32	11.13	11.74	12.69	18.89	19.42	20.94
20-59			105	18.17	2.35	18.08	12.55	14.6	14.96	21.47	21.97	22.32	
m		60-93	75	16.49	2.85	16.38	11.08	12.19	12.91	20.44	21.76	22.5	
Speaking_SDf0	f	20-93	177	28.58	9.73	27.23	11.88	15.1	16.61	41.74	45.83	55.02	

	(Hz)	m	20-93	170	18.87	7.09	17.4	8.86	9.69	10.82	29.12	31.46	39.37
	Speaking _CPPs (dB)	f	20-59	101	10.52	1.57	10.47	7.47	8.01	8.57	12.5	13.17	13.84
			60-74	36	10.9	1.49	10.59	8.42	8.83	9.16	12.88	13.37	13.9
			75-93	31	9.87	1.96	9.43	7.41	7.69	7.81	12.33	12.81	14.74
		m	20-93	171	11.21	2.03	11.02	7.71	8.09	8.52	14.1	14.97	15.47
MPT	MPT (s)	f	20-93	202	14.65	5.82	14.08	5.05	6.69	7.93	21.83	25	32.33
		m	20-93	187	16.62	6.77	15.35	6.57	7.7	9.22	25.71	29.35	36.55
PROSODY	Melodic contrast Q-A (st)	f+m	20-59	228	6.59	4.46	6.98	-1.57	-1.05	0.08	11.7	13.89	17.2
			60-93	161	4.69	5.4	4.7	-5.97	-4.22	-2.46	11.74	13.8	15.98
SPEECH RATE	Rate_Sen tence (ph/s.)	f	20-59	119	11.15	1.67	11.16	7.7	8.41	8.86	13.22	13.78	15.12
			60-93	89	9.75	1.95	9.58	6.23	6.59	6.91	12.31	13.08	13.51
		m	20-59	106	11.53	1.9	11.69	7.08	8.34	8.98	14.04	14.67	14.81
			60-93	79	10.18	1.99	10.15	6.34	6.86	7.14	12.72	13.05	14.72
DDK RATE	AMR _{cv}	f	20-59	117	10.38	1.73	10.64	5.97	7.12	8.06	12.39	12.72	13.36
			60-93	89	9.29	2.08	9.13	5.19	5.61	6.2	12.16	12.54	13.31
		m	20-59	108	10.89	1.82	11.1	6.13	7.44	8.64	13.01	13.65	13.91
			60-93	78	9.44	2.16	9.7	4.9	5.61	6.5	12.15	12.67	14.04
	AMR _{ccv}	f	20-59	119	13.23	2.63	13.51	7.48	8.17	9.57	16.31	17.59	18.54
			60-93	90	11.24	2.71	11.18	5.65	6.85	7.79	14.32	15	17.19
		m	20-59	106	13.88	2.74	14.24	7.15	9.13	10.31	17.01	17.97	18.94
			60-93	78	11.66	2.95	11.52	6.31	6.61	7.67	15.83	16.5	17.27
SMR _{cv} (/badego /)	f	20-59	117	11.67	2.3	11.88	5.32	7.64	8.61	14.22	14.76	16.39	
		60-93	88	9.84	2.58	9.95	5.23	5.83	6.84	12.96	13.75	15.41	
	m	20-59	109	12.18	2.43	12.59	4.89	7.8	8.65	15.17	15.68	16.49	
		60-93	78	10.33	2.68	9.98	5.26	6.12	7.11	13.77	15.17	15.66	

SMR _{CV} - AMR _{CV}	f+m	20-59	222	1.3	1.55	1.41	-2.48	-1.09	-0.74	3.2	3.74	4.71
		60-74	91	0.94	1.52	1.12	-3.3	-1.86	-0.71	2.77	3.365	3.827
		75-93	78	0.6	1.08	0.55	-1.52	-1	-0.66	1.82	2.47	3.34

684

685

686 **Table A.II.** Reference values for Intelligibility (in terms of number of word not recognized over
 687 15 words) and articulation accuracy (in terms of segmental errors over 151 targets). Centiles
 688 1, 5, 50, 95, 99 and maximum error.

	<i>Age Groups</i>	<i>median</i>	<i>1st</i>	<i>5th</i>	<i>10th</i>	<i>90th</i>	<i>95th</i>	<i>99th</i>	<i>maximum</i>
# words not recognized	20-74	0	0	0	0	1	1	2	3
	75-93	0	0	0	0	1	1.5	3.5	5
# segmental errors	20-59	0	0	0	0	1	2	4	5
	60-74	0	0	0	0	3	4	5	5
	75-93	1	0	0	0	4	5	6	6

689

690

691 **Appendix B.** Deviant scores (*DevS*) per dimensions and MonPaGe total deviance score
 692 (*TotalDevS*) for each of the 80 patients.

patient	age	gender	group	Intelligibility	Articulation	MaxPhonation Time	Voice		Prosody	Speech Rate	DDK				MonPaGe TotalDevS
							a1	a2			A	B	C	D	
Fri01	50	F	FA	0	0	0	0	0	0	0	0	0	0	0	9.0
Fri02	38	F	FA	0	0	0	0	0	0	0	0	0	0	0	8.5
Fri03	36	F	FA	0	0	0	0	0	0	0	0	0	0	0	1.0
Fri04	31	F	FA	0	0	0	0	0	0	0	0	0	0	0	7.0
Fri05	37	F	FA	0	0	0	0	0	0	0	0	0	0	0	3.0
Fri06	24	M	FA	0	0	0	0	0	0	0	0	0	0	0	4.0
Fri07	45	M	FA	0	0	0	0	0	0	0	0	0	0	0	14.0
Fri08	46	M	FA	0	0	0	0	0	0	0	0	0	0	0	6.5
Fri09	29	M	FA	0	0	0	0	0	0	0	0	0	0	0	11.5
Fri10	40	M	FA	0	0	0	0	0	0	0	0	0	0	0	12.5
Wil01	29	M	WD	0	0	0	0	0	0	0	0	0	0	0	6.0
Wil02	44	M	WD	0	0	0	0	0	0	0	0	0	0	0	7.0
Wil03	27	M	WD	0	0	0	0	0	0	0	0	0	0	0	6.5
Wil04	33	M	WD	0	0	0	0	0	0	0	0	0	0	0	5.5
Wil05	31	M	WD	0	0	0	0	0	0	0	0	0	0	0	4.0
Wil06	35	M	WD	0	0	0	0	0	0	0	0	0	0	0	4.0
Wil07	49	M	WD	0	0	0	0	0	0	0	0	0	0	0	3.5
Wil08	25	M	WD	0	0	0	0	0	0	0	0	0	0	0	8.5
Wil09	44	F	WD	0	0	0	0	0	0	0	0	0	0	0	8.0
Wil10	35	M	WD	0	0	0	0	0	0	0	0	0	0	0	3.0
ALS01	61	F	ALS	0	0	0	0	0	0	0	0	0	0	0	6.5
ALS02	45	F	ALS	0	0	0	0	0	0	0	0	0	0	0	7.0
ALS03	66	F	ALS	0	0	0	0	0	0	0	0	0	0	0	1.5
ALS04	58	M	ALS	0	0	0	0	0	0	0	0	0	0	0	6.0
ALS05	60	M	ALS	0	0	0	0	0	0	0	0	0	0	0	4.0
ALS06	46	M	ALS	0	0	0	0	0	0	0	0	0	0	0	0.5
ALS07	63	M	ALS	0	0	0	0	0	0	0	0	0	0	0	6.0
ALS08	52	M	ALS	0	0	0	0	0	0	0	0	0	0	0	6.5
ALS09	46	M	ALS	0	0	0	0	0	0	0	0	0	0	0	5.0
ALS10	53	M	ALS	0	0	0	0	0	0	0	0	0	0	0	6.0
Ken01	56	M	SBMA	0	0	0	0	0	0	0	0	0	0	0	2.0
Ken02	70	M	SBMA	0	0	0	0	0	0	0	0	0	0	0	4.0
Ken03	66	M	SBMA	0	0	0	0	0	0	0	0	0	0	0	3.0
Ken04	66	M	SBMA	0	0	0	0	0	0	0	0	0	0	0	4.0
Ken05	72	M	SBMA	0	0	0	0	0	0	0	0	0	0	0	0.0
Ken06	58	M	SBMA	0	0	0	0	0	0	0	0	0	0	0	4.5
Ken07	60	M	SBMA	0	0	0	0	0	0	0	0	0	0	0	4.0
Ken08	76	M	SBMA	0	0	0	0	0	0	0	0	0	0	0	4.0
Ken09	64	M	SBMA	0	0	0	0	0	0	0	0	0	0	0	3.0
Ken10	73	M	SBMA	0	0	0	0	0	0	0	0	0	0	0	3.5
Par01	72	F	PD	0	0	0	0	0	0	0	0	0	0	0	3.0
Par02	81	F	PD	0	0	0	0	0	0	0	0	0	0	0	2.5
Par03	75	F	PD	0	0	0	0	0	0	0	0	0	0	0	7.0
Par04	79	F	PD	0	0	0	0	0	0	0	0	0	0	0	3.5
Par05	69	F	PD	0	0	0	0	0	0	0	0	0	0	0	5.0
Par06	74	F	PD	0	0	0	0	0	0	0	0	0	0	0	9.0
Par07	65	M	PD	0	0	0	0	0	0	0	0	0	0	0	3.0
Par08	76	M	PD	0	0	0	0	0	0	0	0	0	0	0	2.5
Par09	58	M	PD	0	0	0	0	0	0	0	0	0	0	0	0.0
Par10	65	M	PD	0	0	0	0	0	0	0	0	0	0	0	4.5
Par11	73	F	PD	0	0	0	0	0	0	0	0	0	0	0	2.5
Par12	73	M	PD	0	0	0	0	0	0	0	0	0	0	0	0.0
Par13	59	M	PD	0	0	0	0	0	0	0	0	0	0	0	2.5
Par14	56	M	PD	0	0	0	0	0	0	0	0	0	0	0	2.5
Par15	70	F	PD	0	0	0	0	0	0	0	0	0	0	0	4.0
Par16	55	M	PD	0	0	0	0	0	0	0	0	0	0	0	1.5
Par17	55	M	PD	0	0	0	0	0	0	0	0	0	0	0	0.5
Par18	64	M	PD	0	0	0	0	0	0	0	0	0	0	0	6.0
Par19	69	M	PD	0	0	0	0	0	0	0	0	0	0	0	3.5
Par20	70	M	PD	0	0	0	0	0	0	0	0	0	0	0	0.0
ALS11	73	M	ALS	0	0	0	0	0	0	0	0	0	0	0	1.5
ALS12	72	M	ALS	0	0	0	0	0	0	0	0	0	0	0	3.0
ALS13	72	M	ALS	0	0	0	0	0	0	0	0	0	0	0	3.5
ALS14	81	F	ALS	0	0	0	0	0	0	0	0	0	0	0	3.0
ALS15	74	M	ALS	0	0	0	0	0	0	0	0	0	0	0	7.5
ALS16	73	F	ALS	0	0	0	0	0	0	0	0	0	0	0	5.5
ALS17	71	F	ALS	0	0	0	0	0	0	0	0	0	0	0	1.0
ALS18	77	F	ALS	0	0	0	0	0	0	0	0	0	0	0	0.5
ALS19	75	F	ALS	0	0	0	0	0	0	0	0	0	0	0	4.5
ALS20	75	F	ALS	0	0	0	0	0	0	0	0	0	0	0	7.0
AoS01	54	M	AoS	0	0	0	0	0	0	0	0	0	0	0	10.0
AoS02	24	M	AoS	0	0	0	0	0	0	0	0	0	0	0	2.5
AoS03	60	M	AoS	0	0	0	0	0	0	0	0	0	0	0	8.5
AoS04	61	F	AoS	0	0	0	0	0	0	0	0	0	0	0	4.0
AoS05	32	F	AoS	0	0	0	0	0	0	0	0	0	0	0	7.0
AoS06	72	F	AoS	0	0	0	0	0	0	0	0	0	0	0	3.0
AoS07	43	F	AoS	0	0	0	0	0	0	0	0	0	0	0	5.0
AoS08	54	F	AoS	0	0	0	0	0	0	0	0	0	0	0	7.5
AoS09	72	F	AoS	0	0	0	0	0	0	0	0	0	0	0	11.5
AoS10	53	M	AoS	0	0	0	0	0	0	0	0	0	0	0	6.5

within normal range (0)
 mildly deviant (1)
 moderate deviant (2)
 severe deviant (3)
 excessive deviant (4)

missing data

Voice:
 a1 /a/ F0 SD
 a2 Speaking F0 SD
 b /a/ Jitter
 c /a/ Shimmer
 d1 /a/ CPPS
 d2 Speaking CPPS

DDK:
 A CCV AMR
 B CV AMR
 C CV SMR
 D (CV SMR) - (CV AMR)

FA Friedreich Ataxia
 WD Wilson disease
 ALS Amyotrophic Lateral Sclerosis
 PD Parkinson disease
 AoS Apraxia of Speech (post stroke)
 SBMA Spinal and Bulbar Muscular Atrophy
 (Kennedy disease)

693

694 **Appendix C.**

695 Deviant scores (*DevS*) per dimension and MonPaGe total deviance score (*TotalDevS*) for each
 696 of the 62 test controls.

participant	gender	age	Intelligence	Articulation (Pseudow)	MaxPhonation Time	Voice		Prosody	Speech Rate	DDK				MonPaGe Total DevScore
						a1	a2			A	B	C	D	
CTRL1	M	38	1							#	#	#	#	3.0
CTRL2	M	45		2										2.0
CTRL3	F	31		3										2.0
CTRL4	F	26												0.0
CTRL5	F	25												0.0
CTRL6	F	33					4							2.0
CTRL7	F	29			1									1.0
CTRL8	M	30												0.0
CTRL9	F	26							1			#		1.5
CTRL10	F	82					4							1.5
CTRL11	M	65												0.0
CTRL12	F	60												0.0
CTRL13	F	62												0.0
CTRL14	M	50					#							1.0
CTRL15	M	63												0.0
CTRL16	F	64												0.0
CTRL17	M	68												0.0
CTRL18	F	60												0.0
CTRL19	F	48												0.0
CTRL20	F	47		2										2.0
CTRL21	F	56												0.0
CTRL22	F	65												0.0
CTRL23	F	61												0.0
CTRL24	M	73												0.0
CTRL25	F	79												0.0
CTRL26	M	50												0.0
CTRL27	M	25												0.0
CTRL28	F	54												0.0
CTRL29	F	65			2	NA								2.0
CTRL30	F	59												0.0
CTRL31	M	80												0.0
CTRL32	F	62					1							0.5
CTRL33	F	76			NA							#		2.5
CTRL34	F	76												0.0
CTRL35	M	77												0.0
CTRL36	F	25												0.0
CTRL37	F	67												0.0
CTRL38	F	28												0.0
CTRL39	F	50												0.0
CTRL40	F	83												0.0
CTRL41	M	35												0.0
CTRL42	F	60												0.0
CTRL43	M	58												0.0
CTRL44	F	82												0.0
CTRL45	F	27												0.0
CTRL46	F	55							2					2.0
CTRL47	M	35												0.0
CTRL48	M	47												0.0
CTRL49	F	82												0.0
CTRL50	M	62		1										1.0
CTRL51	F	53					#					1		1.0
CTRL52	F	81												0.5
CTRL53	M	88			1							1		1.5
CTRL54	F	27												0.0
CTRL55	M	24		2										2.0
CTRL56	F	25												0.0
CTRL57	F	22												0.0
CTRL58	F	70		2										2.0
CTRL59	F	72												0.0
CTRL60	M	70												0.0
CTRL61	M	72												0.5
CTRL62	M	27												0.0

■ within normal range (0)
■ mildly deviant (1)
■ moderate deviant (2)
■ severe deviant (3)
■ excessive deviant (4)

missing data

Voice:
 a1 /a/ F0 SD
 a2 Speaking F0 SD
 b /a/ Jitter
 c /a/ Shimmer
 d1 /a/ CPPS
 d2 Speaking CPPS

DDK:
 A CCV AMR
 B CV AMR
 C CV SMR
 D (CV SMR) - (CV AMR)

697